AssetMark’s Intellia Therapeutics NTLA Stock Holding History
Bought
Maintained
Sold
Other funds holding NTLA
AssetMark's NTLA Position: Q3 2026 in Review
AssetMark reduced its Intellia Therapeutics (NTLA) stake by 52% in Q3 2026, selling an estimated $213 and leaving 16 shares worth $193. The position accounts for ﹤0.01% of the portfolio, ranked #3618.
AssetMark first reported a position in NTLA in Q4 2021 and has held it in 6 quarters since. The position peaked at $4K in Q4 2021. 239 funds tracked by Wall St. Rank hold NTLA as of Q3 2026.
- AssetMark held 16 shares of Intellia Therapeutics worth $193 as of Q3 2026.
- AssetMark sold 17 Intellia Therapeutics shares in Q3 2026, an estimated $213.
- Intellia Therapeutics made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #3618 holding.
- AssetMark first reported a position in Intellia Therapeutics in Q4 2021 and has held it in 6 quarters since.
- AssetMark's Intellia Therapeutics position peaked at $4K in Q4 2021.
- 239 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2026.
Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.